A Recurrence Nomogram for Hepatoid Adenocarcinoma of the Stomach

A Recurrence Nomogram to Guide Surveillance Strategies After the Resection of Hepatoid Adenocarcinoma of the Stomach: a China Hepatoid Adenocarcinoma of the Stomach Study Group Database Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05274464

Enrollment

261

Registered

2022-03-10

Start date

2004-04-01

Completion date

2019-12-31

Last updated

2022-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Keywords

Reurrence-free survival, Nomogram

Brief summary

This study aims to develop a nomogram to predict postoperative recurrence of HAS and guide individually tailored surveillance strategies.

Detailed description

Patients were included from the China Hepatoid Adenocarcinoma of the Stomach Study Group (China-HASSG) database, which comprises 14 tertiary referral centers. All the patients who had undergone complete resection of a primary HAS between April 2004 and December 2019 were included. First, univariate analysis was performed in Cox regression to identify the risk factors associated with RFS. Next, variables with P\< 0.05 in univariable analysis were included in the multivariable model, and the forward likelihood ratio method was used for analysis to confirm the independent prognostic factors associated with RFS. Finally, based on the results of multivariable analysis, variables that achieved significance at P\< 0.05 were selected to formulate a nomogram.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients who had undergone complete resection of a primary HAS between April 2004 and December 2019

Exclusion criteria

* Patients with metastatic disease, patients who had undergone palliative surgery, patients who had died within 30 days, and patients who were lost to follow-up

Design outcomes

Primary

Measure	Time frame	Description
Reurrence-free survival	3 year	Reurrence-free survival was defined as the time interval from the date of the operation to the date of first recurrence or death from any cause.

Countries

China

Outcome results